Two patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2041. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2041
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2023 to 2042.
US 11,593,656
Using a First Stain to Train a Model to Predict the Region Stained by a Second Stain
Oct 8, 2041
US 11,651,863
Predicting Prostate Cancer Recurrence Using a Prognostic Model that Combines Immunohistochemical Staining and Gene Expression Profiling
Feb 3, 2042
20272031203520392042
Every computed term in this portfolio is shown above.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Oct 2041 · High confidence
Also notable
Ends Feb 2042 · High confidence
Using a First Stain to Train a Model to Predict the Region Stained by a Second Stain
US 11,593,656
The most cited patent in this portfolio, cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2041.
Predicting Prostate Cancer Recurrence Using a Prognostic Model that Combines Immunohistochemical Staining and Gene Expression Profiling
US 11,651,863
Granted 2023. Computed term ends 2042.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,593,656 | Using a First Stain to Train a Model to Predict the Region Stained by a Second Stain In force · High confidence | In force | High confidence | |
| US 11,651,863 | Predicting Prostate Cancer Recurrence Using a Prognostic Model that Combines Immunohistochemical Staining and Gene Expression Profiling In force · High confidence | In force | High confidence |
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.